Venture Capital firm with offices in the US, Canada and Europe focuses on seed and series A and B investments in early stage biotechnology companies, as well as growth equity investments in medical devices companies. The firm’s typical investment size for early stage companies is $5M-$15M and the firm can allocate up to $35-40M total over the life of an investment. The firm focuses on companies that are based in the U.S., Canada and Europe and is actively seeking new investment opportunities.
In early 2017, the firm closed its newest fund that will use a diversified global investment strategy to find, form and fund innovative healthcare companies with an emphasis on novel therapeutics. The fund will invest in approximately 20‐25 biotechnology companies in the U.S., Canada and Europe.
The firm is opportunistic in terms of subsectors and indications. The firm is interested in novel small molecule and biologic therapeutics that address oncology, orphan or genetic based diseases, inflammation, infectious diseases, fibrosis and CNS indications. The firm also is interested in regenerative medicine. In medical devices, the firm is generally agnostic to subsector, but is more interested in revenue-generating devices that address cardiovascular, orthopedic, ophthalmic and neurological disorders. The firm prefers devices with proof-of-concept and strong IP.
The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology. The firm generally is flexible with management teams.
If you are interested in more information about this investor and other investors tracked by LSN, please email email@example.com